Bone Historical Balance Sheet

BBLG Stock

USD 0.85 0.01 1.16%

Trend analysis of Bone Biologics Corp balance sheet accounts such as Total Assets of 2.5 M, Cash of 2.1 M or Cash And Short Term Investments of 2.3 M provides information on Bone Biologics' total assets, liabilities, and equity, which is the actual value of Bone Biologics Corp to its prevalent stockholders. By breaking down trends over time using Bone Biologics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Bone Biologics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bone Biologics Corp is a good buy for the upcoming year.

Bone Biologics Inventory

(495,823)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Bone Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bone Biologics Corp at a specified time, usually calculated after every quarter, six months, or one year. Bone Biologics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bone Biologics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bone currently owns. An asset can also be divided into two categories, current and non-current.

Bone Biologics Balance Sheet Chart

At this time, Bone Biologics' Long Term Debt is most likely to increase significantly in the upcoming years. The Bone Biologics' current Net Working Capital is estimated to increase to about 3.7 M, while Total Assets are projected to decrease to roughly 2.5 M.

Common Stock Shares Outstanding Other Current Liab Total Current Liabilities Other Stockholder Equity

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Current Liabilities

Total Current Liabilities is an item on Bone Biologics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bone Biologics Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Bone Biologics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2023	2024	2025 (projected)
Total Current Liabilities	831.4K	377.7K	358.8K
Other Current Liabilities	470.7K	4.7K	4.4K

Total Current Liabilities Other Current Liab

Bone Biologics balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Other Stockholder Equity	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Net Receivables	Non Current Liabilities Total	Inventory	Short Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital
Common Stock Shares Outstanding		-0.37	-0.25	-0.34	-0.41	-0.37	-0.5	-0.36	0.28	0.58	-0.55	-0.54	-0.6	-0.68	-0.36	-0.33	0.06	-0.15	-0.33	-0.52	-0.13	0.6	-0.12	0.63	-0.47	-0.19
Total Assets	-0.37		-0.67	0.99	0.76	1.0	0.56	-0.14	0.63	-0.48	0.61	-0.29	-0.11	0.57	0.7	-0.28	0.73	-0.17	0.47	0.33	-0.59	-0.48	0.42	-0.37	0.41	0.9
Net Debt	-0.25	-0.67		-0.69	-0.36	-0.67	-0.08	0.58	-0.99	0.06	-0.21	0.89	0.74	0.02	-0.4	0.74	-0.93	0.19	-0.28	0.16	0.82	0.04	-0.27	-0.08	-0.04	-0.82
Cash	-0.34	0.99	-0.69		0.78	0.99	0.57	-0.14	0.65	-0.5	0.63	-0.32	-0.14	0.57	0.73	-0.27	0.74	-0.19	0.49	0.39	-0.59	-0.49	0.47	-0.4	0.46	0.94
Cash And Short Term Investments	-0.41	0.76	-0.36	0.78		0.76	0.64	0.36	0.3	-0.57	0.65	0.02	0.02	0.67	0.96	0.12	0.41	0.22	0.6	0.54	-0.19	-0.61	0.59	-0.49	0.56	0.64
Total Current Assets	-0.37	1.0	-0.67	0.99	0.76		0.56	-0.14	0.63	-0.48	0.61	-0.29	-0.11	0.57	0.7	-0.28	0.73	-0.17	0.47	0.33	-0.59	-0.48	0.42	-0.37	0.41	0.9
Other Current Liab	-0.5	0.56	-0.08	0.57	0.64	0.56		0.25	-0.01	-0.36	0.42	0.29	0.46	0.45	0.59	0.09	0.04	-0.09	0.28	0.44	0.07	-0.53	0.0	-0.49	0.24	0.44
Total Current Liabilities	-0.36	-0.14	0.58	-0.14	0.36	-0.14	0.25		-0.61	-0.24	0.16	0.69	0.48	0.33	0.29	0.72	-0.51	0.4	-0.1	0.4	0.34	-0.23	0.11	-0.3	0.26	-0.33
Total Stockholder Equity	0.28	0.63	-0.99	0.65	0.3	0.63	-0.01	-0.61		-0.02	0.16	-0.92	-0.78	-0.06	0.33	-0.74	0.93	-0.21	0.25	-0.21	-0.83	0.01	0.27	0.14	0.02	0.79
Retained Earnings	0.58	-0.48	0.06	-0.5	-0.57	-0.48	-0.36	-0.24	-0.02		-0.96	-0.23	-0.24	-0.93	-0.66	-0.23	-0.33	-0.4	-0.78	-0.8	0.13	0.96	-0.54	0.96	-0.91	-0.51
Other Stockholder Equity	-0.55	0.61	-0.21	0.63	0.65	0.61	0.42	0.16	0.16	-0.96		0.11	0.15	0.93	0.74	0.14	0.43	0.35	0.76	0.79	-0.23	-0.93	0.64	-0.91	0.91	0.65
Total Liab	-0.54	-0.29	0.89	-0.32	0.02	-0.29	0.29	0.69	-0.92	-0.23	0.11		0.91	0.37	-0.06	0.77	-0.78	0.18	-0.05	0.42	0.73	-0.28	-0.14	-0.38	0.2	-0.52
Common Stock	-0.6	-0.11	0.74	-0.14	0.02	-0.11	0.46	0.48	-0.78	-0.24	0.15	0.91		0.36	-0.07	0.5	-0.64	0.06	-0.03	0.41	0.62	-0.28	-0.32	-0.43	0.15	-0.34
Short Long Term Debt Total	-0.68	0.57	0.02	0.57	0.67	0.57	0.45	0.33	-0.06	-0.93	0.93	0.37	0.36		0.7	0.34	0.25	0.36	0.72	0.78	-0.04	-0.91	0.58	-0.88	0.85	0.48
Other Current Assets	-0.36	0.7	-0.4	0.73	0.96	0.7	0.59	0.29	0.33	-0.66	0.74	-0.06	-0.07	0.7		0.07	0.47	0.36	0.68	0.58	-0.21	-0.7	0.66	-0.57	0.65	0.66
Short Term Debt	-0.33	-0.28	0.74	-0.27	0.12	-0.28	0.09	0.72	-0.74	-0.23	0.14	0.77	0.5	0.34	0.07		-0.66	0.05	-0.01	0.51	0.59	-0.26	0.3	-0.28	0.33	-0.4
Net Tangible Assets	0.06	0.73	-0.93	0.74	0.41	0.73	0.04	-0.51	0.93	-0.33	0.43	-0.78	-0.64	0.25	0.47	-0.66		0.0	0.48	-0.03	-0.84	-0.27	0.36	-0.15	0.25	0.85
Accounts Payable	-0.15	-0.17	0.19	-0.19	0.22	-0.17	-0.09	0.4	-0.21	-0.4	0.35	0.18	0.06	0.36	0.36	0.05	0.0		0.38	0.11	0.17	-0.36	0.16	-0.35	0.3	-0.18
Long Term Debt	-0.33	0.47	-0.28	0.49	0.6	0.47	0.28	-0.1	0.25	-0.78	0.76	-0.05	-0.03	0.72	0.68	-0.01	0.48	0.38		0.52	0.0	-0.82	0.56	-0.68	0.68	0.52
Net Receivables	-0.52	0.33	0.16	0.39	0.54	0.33	0.44	0.4	-0.21	-0.8	0.79	0.42	0.41	0.78	0.58	0.51	-0.03	0.11	0.52		0.12	-0.76	0.58	-0.84	0.9	0.36
Non Current Liabilities Total	-0.13	-0.59	0.82	-0.59	-0.19	-0.59	0.07	0.34	-0.83	0.13	-0.23	0.73	0.62	-0.04	-0.21	0.59	-0.84	0.17	0.0	0.12		0.01	-0.18	-0.01	-0.09	-0.71
Inventory	0.6	-0.48	0.04	-0.49	-0.61	-0.48	-0.53	-0.23	0.01	0.96	-0.93	-0.28	-0.28	-0.91	-0.7	-0.26	-0.27	-0.36	-0.82	-0.76	0.01		-0.51	0.95	-0.84	-0.5
Short Long Term Debt	-0.12	0.42	-0.27	0.47	0.59	0.42	0.0	0.11	0.27	-0.54	0.64	-0.14	-0.32	0.58	0.66	0.3	0.36	0.16	0.56	0.58	-0.18	-0.51		-0.37	0.76	0.49
Property Plant Equipment	0.63	-0.37	-0.08	-0.4	-0.49	-0.37	-0.49	-0.3	0.14	0.96	-0.91	-0.38	-0.43	-0.88	-0.57	-0.28	-0.15	-0.35	-0.68	-0.84	-0.01	0.95	-0.37		-0.84	-0.41
Current Deferred Revenue	-0.47	0.41	-0.04	0.46	0.56	0.41	0.24	0.26	0.02	-0.91	0.91	0.2	0.15	0.85	0.65	0.33	0.25	0.3	0.68	0.9	-0.09	-0.84	0.76	-0.84		0.48
Net Invested Capital	-0.19	0.9	-0.82	0.94	0.64	0.9	0.44	-0.33	0.79	-0.51	0.65	-0.52	-0.34	0.48	0.66	-0.4	0.85	-0.18	0.52	0.36	-0.71	-0.5	0.49	-0.41	0.48

Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	51.1K	43.1K	47.6K	263.1K	1.5M	1.3M
Total Assets	0.0	6.7M	8.5M	3.7M	3.9M	2.5M
Net Debt	11.7M	(6.7M)	(7.5M)	(3.0M)	(3.3M)	(3.2M)
Cash	0.0	6.7M	7.5M	3.0M	3.3M	2.1M
Total Current Assets	0.0	6.7M	8.5M	3.7M	3.9M	2.5M
Other Current Liab	535.6K	1.5M	2.5M	470.7K	4.7K	4.4K
Total Current Liabilities	13.7M	99.9K	2.5M	831.4K	377.7K	358.8K
Total Stockholder Equity	(13.7M)	6.6M	5.9M	2.9M	3.5M	3.7M
Retained Earnings	(68.9M)	(70.5M)	(72.0M)	(80.9M)	(85.0M)	(80.8M)
Other Stockholder Equity	55.2M	77.0M	77.9M	83.8M	88.5M	51.6M
Total Liab	13.7M	99.9K	2.5M	831.4K	377.7K	358.8K
Other Current Assets	85.3K	6.7K	956.9K	711.2K	536.2K	292.3K
Net Tangible Assets	(8.6M)	(11.9M)	(13.7M)	6.6M	7.6M	7.9M
Accounts Payable	465.4K	99.9K	888.46	360.7K	373.0K	221.8K
Net Invested Capital	(2.0M)	6.6M	5.9M	2.9M	3.5M	2.3M
Net Working Capital	(13.7M)	6.6M	5.9M	2.9M	3.5M	3.7M

Currently Active Assets on Macroaxis

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria
HMY	Harmony Gold Mining
FSM	Fortuna Silver Mines

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:

How To Invest In Bone

Details

Is Bone Stock a good investment?

Details

What is Bone Biologics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.83)

Return On Assets

(0.69)

Return On Equity

(1.29)

The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Common Stock Shares Outstanding	Total Assets
Net Debt	Cash
Cash And Short Term Investments	Liabilities And Stockholders Equity
Total Current Assets	Other Current Liab
Total Current Liabilities	Total Stockholder Equity
Retained Earnings	Other Stockholder Equity
Total Liab	Common Stock
Short Long Term Debt Total	Other Current Assets
Short Term Debt	Net Tangible Assets
Property Plant And Equipment Net	Accounts Payable
Non Current Assets Total	Non Currrent Assets Other
Other Assets	Long Term Debt
Net Receivables	Non Current Liabilities Total
Inventory	Short Long Term Debt
Accumulated Other Comprehensive Income	Property Plant Equipment
Accumulated Amortization	Other Liab
Total Permanent Equity	Warrants
Noncontrolling Interest In Consolidated Entity	Good Will
Common Stock Total Equity	Retained Earnings Total Equity
Short Term Investments	Long Term Debt Total
Capital Surpluse	Capital Lease Obligations
Negative Goodwill	Additional Paid In Capital
Deferred Long Term Liab	Preferred Stock Redeemable
Long Term Investments	Property Plant And Equipment Gross
Preferred Stock Total Equity	Treasury Stock
Non Current Liabilities Other	Accumulated Depreciation
Deferred Long Term Asset Charges	Intangible Assets
Temporary Equity Redeemable Noncontrolling Interests	Current Deferred Revenue
Net Invested Capital	Net Working Capital
Capital Stock

Bone Historical Balance Sheet

Bone Biologics Inventory

(495,823)

About Bone Balance Sheet Analysis

Bone Biologics Balance Sheet Chart

Common Stock Shares Outstanding

Total Current Liabilities

Bone Biologics balance sheet Correlations

Bone Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bone Biologics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Other Current Assets	+ 0.96	Cash And Short Term Investments
Inventory	+ 0.96	Retained Earnings
Property Plant Equipment	+ 0.96	Retained Earnings

Total Stockholder Equity	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Inventory	- 0.93	Other Stockholder Equity
Short Long Term Debt Total	- 0.93	Retained Earnings
Net Tangible Assets	- 0.93	Net Debt
Total Liab	- 0.92	Total Stockholder Equity